Karen L. Smith
CIK 1639637 · Chief Medical Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.47M
Companies
12
Total Filings
55
Lifetime Open-Market Net
-$2.68M
Filer Profile
Reported Address
C/O JAZZ PHARMACEUTICALS PLC5TH FL, WATERLOO EXCHANGE, WATERLOO RD
DUBLIN L2 4, L2 0
Related Filers
Emergent BioSolutions Inc. — 3 joint filings, latest 2021-05-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CNTX | Director | — | $0.35 | — | $0 | 3 | 2026-06-26 |
| SKYE | Director | — | $2.04 | — | $0 | 5 | 2026-04-02 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 102,100 | $0.18 | $18.1K | $0 | 9 | 2025-06-16 |
| AUPH | Director | 24,807 | $16.10 | $399.4K | -$44.2K | 3 | 2024-11-25 |
| Tourmaline Bio, Inc. (TALS) Delisted | Director | — | $27.20 | — | $0 | 3 | 2023-06-14 |
| QNCX | Chief Medical Officer | — | $29.55 | — | $0 | 1 | 2023-02-02 |
| Quince Therapeutics, Inc. (CRTX) Delisted | Chief Medical Officer | 194,690 | $1.95 | $379.6K | $0 | 2 | 2022-05-27 |
| ACCELERON PHARMA INC (XLRN) Delisted | Director | 0 | $178.75 | $0 | -$2.88M | 8 | 2021-11-22 |
| ANTARES PHARMA, INC. (ATRS) Delisted | Director | 79,645 | $5.59 | $445.2K | $0 | 4 | 2021-06-14 |
| EBS | EVP, Chief Medical Officer | 11,888 | $6.23 | $74.1K | $0 | 2 | 2021-05-11 |
| JAZZ | EVP, R&D and CMO | 28,474 | $245.80 | $7.00M | $250.0K | 13 | 2018-03-07 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | — | — | — | $0 | 1 | 2018-02-13 |
Recent Filings · Page 2 of 6
55 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-07-05 | SKYE | Grant (A) | — | $0 | EDGAR |
| 2024-06-06 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +25,000 | $0 | EDGAR |
| 2023-08-21 | AUPH | Grant (A) | — | $0 | EDGAR |
| 2023-06-14 | Tourmaline Bio, Inc. (TALS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-05 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +13,900 | $0 | EDGAR |
| 2023-02-02 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2022-06-13 | Tourmaline Bio, Inc. (TALS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-27 | Quince Therapeutics, Inc. (CRTX) Delisted | Grant (A) | +170,354 | $0 | EDGAR |
| 2022-05-26 | — | Disp (D) | −79,645 | -$446.0K | |
| 2022-05-23 | Quince Therapeutics, Inc. (CRTX) Delisted | Grant (A) | +24,336 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.